Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877006 · ClinicalTrials.gov registry record · Phase 3
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
A Phase 3 study of Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
- 20
- Study locations
NCT00877006 is a Phase 3 study of Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 447 participants, above the 100-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (347% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00877006, a Phase 3 study of Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG rituximab
- DRUG bendamustine
- DRUG vincristine
Study Locations (20)
California
- Teva Investigational Site 11 - Corona
- Teva Investigational Site 21 - Fountain Valley
- Teva Investigational Site 52 - Fountain Valley
- Teva Investigational Site 64 - Fullerton
- Teva Investigational Site 40 - Los Angeles
- Teva Investigational Site 53 - Los Angeles
- Teva Investigational Site 57 - San Diego
Florida
- Teva Investigational Site 58 - Fort Myers
- Teva Investigational Site 38 - Hollywood
- Teva Investigational Site 23 - Jacksonville
- Teva Investigational Site 65 - Lake Worth
- Teva Investigational Site 156 - Miami
Colorado
- Teva Investigational Site 15 - Aurora
- Teva Investigational Site 155 - Denver
- Teva Investigational Site 5 - Fort Collins
Connecticut
- Teva Investigational Site 70 - New Britain
- Teva Investigational Site 37 - Norwalk
- Teva Investigational Site 67 - Southington
Arizona
- Teva Investigational Site 165 - Tucson
Arkansas
- Teva Investigational Site 167 - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2009-04-30 |
| Est. Completion | 2012-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877006
The ClinicalTrials.gov registry entry for NCT00877006 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 100-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (347% higher). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT00877006 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00877006 about?
NCT00877006 is a clinical study titled "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study". The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and predni...
What is the current status of trial NCT00877006?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2009-04-30. Estimated completion is 2012-03-31.
What conditions does trial NCT00877006 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00877006?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), rituximab (DRUG), bendamustine (DRUG), vincristine (DRUG).
Who is sponsoring clinical trial NCT00877006?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00877006 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RECRUITING · Phase 3
-
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
COMPLETED · Phase 3
-
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.